Guilin Sanjin Pharmaceutical Co Ltd (002275) - Total Assets

Latest as of September 2025: CN¥4.30 Billion CNY ≈ $629.19 Million USD

Based on the latest financial reports, Guilin Sanjin Pharmaceutical Co Ltd (002275) holds total assets worth CN¥4.30 Billion CNY (≈ $629.19 Million USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. Explore cash flow to debt ratio of Guilin Sanjin Pharmaceutical Co Ltd to assess how comfortably operating cash covers total debt obligations.

Guilin Sanjin Pharmaceutical Co Ltd - Total Assets Trend (2006–2024)

This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's total assets have evolved over time, based on quarterly financial data. See 002275 total equity for net asset value and shareholders' equity analysis.

Guilin Sanjin Pharmaceutical Co Ltd - Asset Composition Analysis

Current Asset Composition (December 2024)

Guilin Sanjin Pharmaceutical Co Ltd's total assets of CN¥4.30 Billion consist of 60.6% current assets and 39.4% non-current assets.

Asset Category Amount (CNY) % of Total Assets
Cash & Equivalents CN¥0.00 24.8%
Accounts Receivable CN¥645.36 Million 15.3%
Inventory CN¥208.29 Million 4.9%
Property, Plant & Equipment CN¥0.00 0.0%
Intangible Assets CN¥141.55 Million 3.3%
Goodwill CN¥5.70 Million 0.1%

Asset Composition Trend (2006–2024)

This chart illustrates how Guilin Sanjin Pharmaceutical Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Guilin Sanjin Pharmaceutical Co Ltd market cap and net worth.

Key Asset Composition Facts

  • Current vs. Non-Current Assets: Guilin Sanjin Pharmaceutical Co Ltd's current assets represent 60.6% of total assets in 2024, an increase from 56.1% in 2006.
  • Cash Position: Cash and equivalents constituted 24.8% of total assets in 2024, up from 23.7% in 2006.
  • Tangible vs. Intangible: Intangible assets (including goodwill) make up 3.0% of total assets, unchanged from 3.0% in 2006.
  • Asset Diversification: The largest asset category is accounts receivable at 15.3% of total assets.

Guilin Sanjin Pharmaceutical Co Ltd Competitors by Total Assets

Key competitors of Guilin Sanjin Pharmaceutical Co Ltd based on total assets are shown below.

Company Country Total Assets
Tianjin Zhongxin Pharmaceutical Group Corp Ltd
SHG:600329
China CN¥11.59 Billion
Chengdu Kanghong Pharmaceuticals Group Co Ltd
SHE:002773
China CN¥10.21 Billion
China Resources Double-Crane Pharmaceutical Co Ltd
SHG:600062
China CN¥17.01 Billion
Zhejiang Hisun Pharmaceutical Co Ltd
SHG:600267
China CN¥13.81 Billion
Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt
F:RIG2
Germany €1.60 Trillion
Zhejiang Tianyu Pharmaceutical Co Ltd
SHE:300702
China CN¥6.56 Billion
Zhejiang Garden Bio-chemical High-tech Co Ltd
SHE:300401
China CN¥5.91 Billion
KPC Pharmaceuticals Inc
SHG:600422
China CN¥12.01 Billion

Guilin Sanjin Pharmaceutical Co Ltd - Liquidity and Working Capital Analysis

Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.

Key Liquidity Metrics

Metric Current 1 Year Ago 5 Years Ago
Current Ratio 3.13 3.80 4.04
Quick Ratio 2.84 3.37 3.71
Cash Ratio 0.00 0.00 0.00
Working Capital CN¥1.71 Billion CN¥1.67 Billion CN¥1.79 Billion

Guilin Sanjin Pharmaceutical Co Ltd - Advanced Valuation Insights

This section examines the relationship between Guilin Sanjin Pharmaceutical Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.

Key Valuation Metrics

Current Price-to-Book Ratio 2.62
Latest Market Cap to Assets Ratio 0.27
Asset Growth Rate (YoY) 7.5%
Total Assets CN¥4.23 Billion
Market Capitalization $1.14 Billion USD

Valuation Analysis

Below Book Valuation: The market values Guilin Sanjin Pharmaceutical Co Ltd's assets below their book value (0.27x), which may indicate investor concerns about asset quality or future growth.

Positive Asset Growth: Guilin Sanjin Pharmaceutical Co Ltd's assets grew by 7.5% over the past year, showing continued investment in the company's operational capacity.

Annual Total Assets for Guilin Sanjin Pharmaceutical Co Ltd (2006–2024)

The table below shows the annual total assets of Guilin Sanjin Pharmaceutical Co Ltd from 2006 to 2024.

Year Total Assets Change
2024-12-31 CN¥4.23 Billion
≈ $619.31 Million
+7.52%
2023-12-31 CN¥3.94 Billion
≈ $575.97 Million
-0.73%
2022-12-31 CN¥3.96 Billion
≈ $580.19 Million
-3.20%
2021-12-31 CN¥4.10 Billion
≈ $599.35 Million
+5.50%
2020-12-31 CN¥3.88 Billion
≈ $568.10 Million
+13.66%
2019-12-31 CN¥3.42 Billion
≈ $499.81 Million
+0.28%
2018-12-31 CN¥3.41 Billion
≈ $498.42 Million
+5.47%
2017-12-31 CN¥3.23 Billion
≈ $472.59 Million
+12.53%
2016-12-31 CN¥2.87 Billion
≈ $419.95 Million
+3.99%
2015-12-31 CN¥2.76 Billion
≈ $403.83 Million
-0.86%
2014-12-31 CN¥2.78 Billion
≈ $407.33 Million
+3.51%
2013-12-31 CN¥2.69 Billion
≈ $393.51 Million
+8.21%
2012-12-31 CN¥2.49 Billion
≈ $363.66 Million
+12.91%
2011-12-31 CN¥2.20 Billion
≈ $322.07 Million
+11.09%
2010-12-31 CN¥1.98 Billion
≈ $289.92 Million
-3.91%
2009-12-31 CN¥2.06 Billion
≈ $301.71 Million
+76.87%
2008-12-31 CN¥1.17 Billion
≈ $170.59 Million
+8.06%
2007-12-31 CN¥1.08 Billion
≈ $157.87 Million
+29.70%
2006-12-31 CN¥831.81 Million
≈ $121.72 Million
--

About Guilin Sanjin Pharmaceutical Co Ltd

SHE:002275 China Drug Manufacturers - Specialty & Generic
Market Cap
$1.14 Billion
CN¥7.79 Billion CNY
Market Cap Rank
#8219 Global
#1845 in China
Share Price
CN¥13.26
Change (1 day)
-1.63%
52-Week Range
CN¥12.08 - CN¥17.38
All Time High
CN¥19.61
About

Guilin Sanjin Pharmaceutical Co., Ltd. engages in the research, production, and sale of traditional Chinese and natural medicines in China and internationally. The company offers three gold particles, Guilin watermelon frost, watermelon frost lozenges, throat clearing spray, Naomaitai capsules, vertigo tablets, Xuanyunning granules, Gejie dingchuan capsule, compound panax notoginseng stomachache … Read more